Comments

Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

Clinical Hematology, Nantes University Hospital, Nantes
Clinical Hematology, Nantes University Hospital, Nantes
Haematologica Early view Jan 30, 2025 https://doi.org/10.3324/haematol.2025.287378